Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2020-03-13 Regulatory Filings
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings
2020-03-13 English
Regulatory Filings 2020
Regulatory Filings
2020-03-03 English
Proxy Solicitation & Information Statement 2020
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Exempt Solicitation pursuant to Rule 14a-103 under the Securities Exchange Act of 1934. It contains written materials submitted voluntarily to influence shareholder voting on a proposed merger with Tarveda. The content is focused on criticizing the current Board's decisions and urging shareholders to vote against the merger proposal. This type of document is related to proxy solicitation activities, where shareholders are solicited to vote on corporate matters. It is not a full report, financial statement, or earnings release, nor is it an announcement of voting results. The document fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or proposals.
2020-03-03 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-6(b) under the Securities Act of 1934, which are typically used for merger communications. The text references a planned reverse merger between Tarveda Therapeutics, Inc. and Organovo Holdings, Inc. It includes detailed information about the company's business, pipeline, leadership, and forward-looking statements, consistent with a presentation or communication related to a merger transaction. The presence of the Rule 425 filing and the detailed business overview indicates this is a merger-related communication rather than a full annual report, earnings release, or other financial report. Therefore, the document fits best under the category of Merger & Acquisition (MA) filings, which include merger communications such as Rule 425 filings.
2020-03-03 English
425 Filing
Proxy Solicitation & Information Statement Classification · 100% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-6(b) under the Securities Act of 1934, which are rules related to merger communications and proxy solicitation. The text repeatedly references a definitive proxy statement/prospectus/information statement related to a proposed merger between Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. It encourages stockholders to vote on merger-related proposals and discusses strategic alternatives and merger rationale. The document is a solicitation letter accompanying or referencing the definitive proxy statement/prospectus/information statement, which is typical of proxy solicitation materials. There is no detailed financial data or full report content, but rather a communication urging shareholders to vote on merger proposals. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI).
2020-02-26 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a filing by Organovo Holdings, Inc. pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-6(b) under the Securities Act of 1934. It discusses the filing of definitive proxy materials related to a proposed merger with Tarveda Therapeutics, Inc. The text includes a letter to stockholders urging them to vote in favor of the merger and other proposals, details about the strategic alternatives process, and information about the merger benefits. The document is clearly related to merger communications and proxy solicitation for a shareholder vote on the merger. It is not the proxy statement itself but a filing under Rule 425, which is used to disseminate merger-related communications. Therefore, the document fits best under the category of Merger & Acquisition filings (MA), which includes merger communications such as Form 425 filings. The document is lengthy and substantive, not a brief announcement or a report publication announcement. Hence, the classification is MA with high confidence.
2020-02-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.